

QUANTITATIVE NUCLEAR MAGNETIC RESONANCE SPECTROSCOPIC METHOD DEVELOPMENT AND VALIDATION OF SUMATRIPTAN SUCCINATE IN PHARMACEUTICAL TABLET DOSAGE FORM

Mangarao Nakka, * Srinivas Nakka

Organic and Biomolecular Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad-500007, India

*Corresponding Author: Email: drmangarao@yahoo.com

Received: 9 January 2018 / Revised: 16 February 2018 / Accepted: 17 February 2018 / Available online 31 March 2018

ABSTRACT

A new, simple and accurate quantitative proton nuclear magnetic resonance (qNMR) spectroscopic method was developed to determine the sumatriptan succinate in pharmaceutical tablet formulation. In this developed quantitative nuclear magnetic resonance spectroscopy method, Maleic acid was used as internal standard (IS) due to there was no overlapping of the peak to analyte peaks and deuterium oxide (D₂O) was used as diluent. For the quantification of the sumatriptan succinate 4.43 ppm and 6.20 ppm peaks were used as quantitative monitoring purpose to correspond to analyte sumatriptane succinate and Maleic acid internal standard (IS) respectively. The final optimized method was validated as per International Conference on Harmonisation (ICH) guidelines in terms of Specificity, Limit of detection (LOD), Limit of Quantitation (LOQ), Precision, Linearity, Accuracy, Solution stability and Robustness. This method could be used to determination of sumatriptane succinate in bulk and pharmaceutical tablet dosage forms.

Keywords – Sumatriptan succinate, Quantitative nuclear magnetic resonance (qNMR), Internal standard, Method Validation

1. INTRODUCTION

Sumatriptan succinate is belong to triptane class and used to treat Migraine^{1,6} and cluster headaches. Sumatriptane succinate was chemically 3-[2-(dimethylamino) Ethyl]-N-methylindole-5-methanesulfonamide. In July 2009, the US FDA approved a single-use jet injector formulation of sumatriptan.




Fig.1: Chemical Structures of Sumatriptan succinate

Nuclear magnetic resonance spectroscopy itself was a quantitative spectroscopic tool due to the intensity of resonance peak is directly proportional to the number of corresponding resonance nuclei. This fact facilitates to determination of the amount of

substance with accurate and precisely. Quantitative NMR spectroscopy^{7,11} was first described by Jungnickel, Forbes and Hollis in 1963. The most attractive advantage with quantitative NMR than other analytical techniques that can achieve precise quantification without analyte reference standards (CRS). Analytical methods based on HPLC^{12,13}, spectrophotometry^{14,16}, UPLC-MS method¹⁷, HPTLC method¹⁸ have been reported for the determination of sumatriptan succinate. The aim of the study was to develop specific and accurate quantitative NMR method to determine the assay of sumatriptan succinate in bulk as well as in pharmaceutical tablet dosage form and validated as per International Conference on Harmonization (ICH)¹⁹ guidelines.

2. MATERIALS AND METHODS

2.1 CHEMICALS AND REAGENTS

Samples of Sumatriptan succinate standard sample obtained from local pharmaceutical company. High purity analytical grade Maleic acid (99.90%) purchased from Sigma-Aldrich and deuterium oxide-D₂O (99.99%), deuterated dimethyl sulfoxide-DMSO-*d*₆ (99.99%) purchased from Merck. Tablets containing 50 mg of sumatriptan succinate were purchased from local market, India.

2.2 EQUIPMENT

All NMR spectral data obtained from BRUKER 400 Avance-III NMR with field strength of 9.4 Tesla and operating at frequency 400.12 MHz for protons. The spectrometer equipped with 5mm BBO (Broad Band Observe) probe with multi nuclear probe head. Semimicro balance was Sartorius with accuracy 0.001 mg.

2.3 PREPARATION OF STOCK SOLUTION

2.3.1 Maleic acid (IS) stock solution preparation

Accurately weighed about 83.33 mg of Maleic acid and transferred to 10 mL volumetric flask (5 mg/0.6 mL), shake it to completely dissolved and made up to the mark with deuterium oxide (D₂O).

2.3.2 Sumatriptan succinate Standard preparation

Accurately weighed about 10 mg of sumatriptan succinate standard in a stoppered glass vial to that added 0.6 mL stock solution of maleic acid (IS), shake it to completely dissolved.

2.3.3 Sumatriptan succinate Sample (Tablets) preparation

Ten tablets of sumatriptan succinate were weighed, crushed with mortar and pestle ground in to fine powder, take portion equivalent to 10 mg of sumatriptan succinate was weighed accurately, transferred to stoppered glass vial to that added 0.6 mL stock solution of maleic acid (IS), the solution was thoroughly mixed it to completely dissolved and supernatant solution was taken for analysis.

3. RESULTS AND DISCUSSION

3.1 Determination of Relaxation Time

To accurate quantification, the key parameter is relaxation delay (*t*) which depend on the longitudinal relaxation time (*T*₁) of all signals of interest. Longitudinal relaxation time (*T*₁) is calculated with following formula (1).

$$M_z = M_0[1 - e^{-(t/T_1)}]$$

Here, *M*_z is the magnetization along z-axis after time *t*

*M*₀ is the magnetization along z-axis at thermal equilibrium

In this study relaxation time was determined experimentally by inversion recovery experiment for all the protons in sumatriptan succinate and maleic acid internal standard in D₂O. The longest relaxation time was found for the maleic acid as 7.89 sec and for the monitoring analyte proton was found to 0.5 sec. The T₁ results were summarized in the table1. Relaxation delay (t) should not be less than five times the T₁ to ensure a reliable experimental data, so that 40sec relaxation time was kept for all experiments.

Table 1: Summarized results for T₁ values of all corresponding protons

S. No	Chemical shift	Relaxation delay(T ₁) sec
1	2.54	1.86
2	2.61	1.29
3	2.78	0.96
4	3.09	0.57
5	3.10	0.54
6	3.31	0.59
7	4.43	0.50
8	6.19	7.89
9	7.14	1.70
10	7.21	5.38
11	7.39	2.60
12	7.41	2.49
13	7.54	1.51

3.2 OPTIMISED DATA ACQUISITION PARAMETERS

The optimized experimental quantitative proton NMR (qNMR) parameters were number of scans (ns) 64 collected for each experiment into 32K datapoints using 30° pulse length. Acquisition time 3.94 sec, Delay time of 40sec as five times of the calculated from the T₁ value. Preacquisition delay 6.5 sec and spectral width (25.0ppm). For all proton NMR spectra data, manual phase correction and base line correction were used for the signal integration.

3.3 Sumatriptan succinate structure confirmation by various NMR experiments

Sumatriptan succinate standard was dissolved in deuterated dimethyl sulfoxide (DMOS-d₆) and performed ¹H-NMR, ¹³C-NMR, DEPT, COSY, HSQC, HMBC and NOESY experiments. The assignment of ¹H-NMR and ¹³C-NMR chemical shifts were assigned and summarized in the table2. The chemical shifts were referenced to the residual DMSO-d₆ peak at 2.50 ppm and 39.7 ppm for ¹H-NMR and ¹³C-NMR respectively.




Fig.2: Structure of sumatriptan succinate

Table 2: Summarized results for assignment of ^1H -NMR & ^{13}C -NMR of sumatriptane succinate

S. No	^1H - NMR			^{13}C - NMR		Assignment
	Chemical shift(ppm)	Multiplicity & Coupling constant ($J=\text{Hz}$)	No.of Protons	Chemical shift(ppm)	No.of Carbon	
1	2.36	s	4	30.7	-2CH ₂ -	17
2	2.41	s	6	43.6	-2CH ₃	1
3	2.53-2.54	d($J=3.9$)	3	29.2	-CH ₃	14
4	2.75-2.79	t($J=8.0$)	2	58.4	-CH ₂ -	3
5	2.87-2.90	t($J=7.0$)	2	21.6	-CH ₂ -	2
6	4.34	s	2	56.8	-CH ₂ -	13
7	6.77-6.81	q($J=5.1$)	1	-	-	15
8	7.07-7.09	dd($J=8.2,1.2$)	1	124.1	-CH-	10
9	7.193-7.198	d($J=2.0$)	1	123.7	-CH-	12
10	7.314-7.334	d($J=8.3$)	1	111.5	-CH-	9
11	7.52	s	1	120.9	-CH-	5
12	10.89	Broad singlet	1	-	-	15
13				111.2	quary-C-	11
14				120.1	quary-C-	7
15				127.2	quary-C-	8
16				136.1	quary-C-	4
17				174.9	-C=O	16





Fig.3: Structure of Maleic acid internal standard

Table 3: Summarised results for assignment of ^1H -NMR & ^{13}C -NMR of Maleic acid (IS)

S. No	^1H -NMR			^{13}C -NMR		Assignment
	Chemical shift(ppm)	Multiplicity & Coupling constant ($J=\text{Hz}$)	No.of Protons	Chemical shift(ppm)	No.of Carbon	
1	6.25	s	2	130.43	-2CH-	1
2	12.67	s	2		-2C=O-OH	2
3			-	167.09	-2C=O-	3






Fig.4 (a) ^1H -NMR spectrum of Sumatriptan succinate standard in DMSO- d_6 (b) ^1H -NMR spectrum of Maleic acid (IS) in DMSO- d_6 .

From the above ^1H -NMR spectra sharp singlet peak at 4.43 ppm chosen as quantitative monitoring peak of analyte and the singlet peak at 6.20 ppm, corresponding to Maleic acid internal standard. The assay and amount of sumatriptan succinate was calculated by using below formula

$$W_{\text{Spl}} = \frac{I_{\text{Spl}}}{I_{\text{Std}}} \times \frac{M_{\text{Spl}}}{M_{\text{Std}}} \times \frac{N_{\text{Std}}}{N_{\text{Spl}}} \times P_{\text{Std}}$$

$$P_{\text{Spl}} = \frac{I_{\text{Spl}}}{I_{\text{Std}}} \times \frac{M_{\text{Spl}}}{M_{\text{Std}}} \times \frac{N_{\text{Std}}}{N_{\text{Spl}}} \times \frac{W_{\text{Std}}}{W_{\text{Spl}}} \times P_{\text{Std}}$$

Here, I_{Spl} =Integral area of analyte proton signal obtained at 4.32 ppm

I_{Std} =Integral area of Maleic acid internal standard proton signal obtained at 6.23 ppm

M_{Spl} =Molar mass of sumatriptane succinate 432.15g/mol

M_{Std} =Molar mass of Maleic acid internal standard 116.07g/mol

N_{Spl} =No.of protons for sumatriptane succinate (2.0)

N_{Std} =No.of protons for Maleic acid internal standard (20.)

W_{Spl} =Weight of analyte,

W_{Std} =Weight of internal standard (Maleic acid)

P_{Std} =Potency of Maleic acid internal standard (99.90%)

3.4 METHOD VALIDATION

The Optimized final method was validated as per ICH guidelines Q2(B) in terms of Specificity, Limit of detection (LOD), Limit of Quantitation (LOQ), Precision (Method precision and Intermediate precision), Linearity, Accuracy, Robustness, Solution stability and mobile phase stability.

3.4.1 SYSTEM SUITABILITY

Systems suitability was evaluated by performing six replicates were analyzing ^1H -NMR spectra recorded. The acceptance criterion for system suitability, the percentage relative standard deviation of the integral value of analyte signal should not be more than 2.0, the average Signal to noise ratio(S/N) of the analyte signal should be more than 150 and the difference of the chemical shift value should not be more than 0.2ppm.The results were summarized in the table 4.


Table 4: Summarized results of system suitability

Sample Name	Integral value	Signal to noise	Chemical shift (ppm)	Difference in chemical shift
Standard solution-1	1.0427	5317.54	4.439	-
Standard solution-2	1.0428	5378.80	4.438	0.001
Standard solution-3	1.0425	5333.63	4.438	0.001
Standard solution-4	1.0425	5338.61	4.437	0.002
Standard solution-5	1.0428	5300.34	4.437	0.002
Standard solution-6	1.0426	5369.33	4.437	0.002

The percentage relative standard deviation of the integral value of analyte signal was found to 0.01%, the average signal to noise ratio was found to be 5339:1 and the difference of the chemical shift value was found to 0.002ppm.

3.4.2 SPECIFICITY

Recorded the ¹H-NMR spectra individually of Sumatriptan succinate standard, sample, Maleic acid internal standard and diluents D₂O. It was observed that there were no interference peaks found at the analyte monitor peak and the maleic acid internal standard peak.






Fig 5: 1H-NMR spectra of (a) Diluent D2O (b) Maleic acid internal standard (c) Sumatriptan succinate sample (d) Sumatriptane succinate standard

3.4.3 PRECISION

Method Precision/reproducibility was performed by six replicate preparations (n=6) of sumatriptane succinate sample were prepared and recorded the ¹H-NMR spectra. The acceptance criterion for method precision was the percentage relative standard deviation(%RSD) for assay results of sumatriptan succinate was not more than 2%.It was found to be 0.01%.Intermediate precision/repeatability was performed by different analyst and on different day by preparing six replicate injections(n=6) of sumatriptan succinate sample were prepared and recorded the ¹H-NMR spectra. The acceptance criterion for method precision was the percentage relative standard deviation(%RSD) for assay results of sumatriptane succinate was not more than 2% and the percent relative standard deviation for twelve preparations(Method precision and intermediate preparation) was not more than 5%.It was found to be 0.01% and 0.01% respectively, the results were summarized in table5.

Table 5: Summarized results of Precision

Sample name	Precision			Intermediate precision		
	Taken drug wt (mg)	Found drug (mg)	%Assay (as such)	Taken drug wt (mg)	Found drug (mg)	%Assay (as such)
Preparation-1	10.44	10.54	99.97	10.18	10.28	99.94
Preparation-2	10.27	10.37	99.95	10.20	10.3	99.93
Preparation-3	10.37	10.47	99.94	10.33	10.43	99.96
Preparation-4	10.25	10.35	99.98	10.24	10.33	99.93
Preparation-5	10.34	10.44	99.97	10.55	10.65	99.93
Preparation-6	10.21	10.31	99.95	10.20	10.29	99.94

3.4.4 LINEARITY

Linearity was established by preparing seven calibration points from 3mg to 20mg (30% to 200%) of sumatriptan succinate drug weight taken. Linearity calibration curve was obtained from integral peak area against the amount of drug found(mg) by using least squares method. The regression coefficient, slope and intercept were calculated. The acceptance criterion for linearity was the regression coefficient should not be less than 0.995. The equation for curve was $y = 0.1069x + 0.001$ and the regression coefficient found to 1.000, indicates that good linearity. The results were summarized in the table6.

Table 6: Summarized results of Linearity

Sample name	Taken drug (mg)	Found drug (mg)	Integral value
Linearity-1	3.29	3.31	0.3549
Linearity-2	5.30	5.34	0.5721
Linearity-3	8.23	8.3	0.888
Linearity-4	10.25	10.34	1.1064
Linearity-5	12.21	12.32	1.3177
Linearity-6	15.45	15.54	1.6622
Linearity-7	20.15	20.26	2.167




Fig 6: Linearity curve of integral value vs found drug amount in mg

3.4.5 LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTITATION (LOQ)

Limit of detection (LOD) and limit of quantitation (LOQ) can be calculated by the standard deviation of the response and slope S of a calibration curve obtained. The LOD and LOQ were calculated by using below formula

$$\text{LOD} = 3.3 \sigma / S$$

$$\text{LOQ} = 10 \sigma / S$$

where σ = the standard deviation of the response

S = the slope of the calibration curve

From the linearity calibration data, calculated the standard deviation of the response was found to 0.00021 and the slope was 0.10191. LOD and LOQ were found to 0.007mg/0.6mL and 0.020 mg/0.6mL.

3.4.6 ACCURACY

The accuracy/Recovery experiment carried out by preparing in triplicate preparations at 50%,100% and 150% levels with respect to the amount of sample preparation. The acceptance criterion for the percentage recovery at 50%,100% and 150% levels should be within the range of 90-110%.It was found to 100.13 to 101.15,the results were shown in table 7.

Table 7: Summarized results of accuracy

Level	Preparation	Taken drug in mg	Found drug in mg	%Recovery
50%	1	5.20	5.26	101.15
	2	5.29	5.34	100.95
	3	5.24	5.29	100.95
100%	1	10.3	10.39	100.87
	2	10.29	10.39	100.97
	3	10.41	10.43	100.19
150%	1	15.2	15.34	100.92
	2	15.35	15.49	100.91
	3	15.10	15.24	100.93

3.4.7 ROBUSTNESS OF THE OPTIMIZED METHOD

To perform the robustness of the method, experimental parameters (No. of scans, Acquisition time, relaxation delay and different analyte) were altered. For that No. of scans was altered from 48 to 80 i.e 64±16 scans. Acquisition time changed from 3 to 5 i.e 4±1 sec. Relaxation delay changed from 30 to 50sec i.e 40±10 sec and the different analyte peak integral value taken at 7.22 ppm instead of 4.43 ppm. The acceptance criterion for robustness was the absolute difference between the results obtained in Repeatability of Sample preparation-1 and those obtained by carrying out modifications in the method was not more than 10.0%.

Table 8: Summary of robustness results

Parameter	Changes	Taken drug in mg	Found drug in mg	%Assay	Absolute difference w.r.t unaltered condition
No. of scans	48	10.28	10.38	99.97	-0.01
	64	10.34	10.44	99.96	NA
	80	10.09	10.19	99.94	0.02
Acquisition time	3	10.33	10.43	99.97	-0.01
	4	10.31	10.41	99.96	NA
	5	10.25	10.35	99.97	-0.01
Delay time(t)	30	10.32	10.42	99.98	-0.02
	40	10.25	10.35	99.96	NA
	50	10.20	10.3	99.97	-0.01
Different analyte peak	7.22ppm	10.16	10.26	99.97	-0.01
	4.43 ppm	10.28	10.44	99.96	-

3.4.8 SOLUTION STABILITY

The solution stability of sumatriptan succinate in this method was performed on standard and sample preparation at initial, after 6Hrs, 12Hrs, 18Hrs, 24Hrs and 48Hrs intervals, recorded the ¹H-NMR spectra and calculated the assay results of the sample and solution preparations, it was found that there was no remarkable change in the assay results shown in table9.

Table 9: Results of solution stability

For Sample solution					For Standard solution			
		Found mg	% Assay	% Difference	Taken mg	Found mg	% Assay	% Difference
Initial	10.24	10.34	99.97	-	10.24	10.33	99.92	-
after 6Hrs	10.24	10.33	99.90	0.07	10.1	10.19	99.93	0.01
After 12Hrs	10.24	10.34	99.96	0.01	10.35	10.15	99.92	0.00
After 18Hrs	10.24	10.34	99.96	0.01	10.22	10.32	99.89	0.03
After 24Hrs	10.24	10.33	99.91	0.06	10.4	10.5	99.93	0.01
After 48Hrs	10.24	10.34	99.97	0.00	10.23	10.33	99.93	0.01

4. CONCLUSION:

In conclusion, A new, simple and accurate quantitative proton nuclear magnetic resonance (qNMR) spectroscopic method was developed to determine the sumatriptan succinate in pharmaceutical tablet formulation and validated as per ICH guidelines. The proposed method meets all acceptance criterion and can be used to determine the Sumatriptan succinate content in bulk and as well as in tablet dosage form.

5. ACKNOWLEDGEMENTS

We gratefully acknowledge SERB, New Delhi, India (PDF/2016/000177) for financial support in the form of NPDF.

REFERENCES

1. Hsu VD. Sumatriptan: a new drug for vascular headache. *Clin Pharm.* 1992; 11:919-29
2. Anon. Sumatriptan for migraine. *Med Lett Drugs Ther.* 1992; 34:91-3.
3. Ferrari MD and the Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. *N Engl J Med.* 1991; 325:316-21.
4. Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. *Drugs.* 1994; 47:622-51.
5. Bousser MG, d'Allens H, Richard A et al. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. *J Int Med.* 1993; 234:211-6.
6. Hoerlein M, McMonigle G, Franz DN. Sumatriptan therapy of pediatric migraines. *Ann Neurol.* 1994; 36:548.
7. F. Kasler, Quantitative analysis by NMR spectroscopy (Academic press, New York, 1973)
8. Holzgrabe U, Diehl B and Wawer I, NMR Spectroscopy in Pharmaceutical Analysis, Elsevier Ltd., Oxford, UK, 2008, 49-50.
9. Rizzo, V, Pinciroli, V, Quantitative NMR in synthetic and combinatorial chemistry. *J. Pharm. Biomed. Anal.* 38:2005, 851-857
10. Malz, F., Jancke, H. Validation of quantitative NMR, *Journal of pharmaceutical and Biomedical analysis.* 38, 2005, 813-823
11. Tanja, B., Curd, S. The role of solvents in the signal separation for quantitative ¹H-NMR spectroscopy, *Journal of pharmaceutical and Biomedical analysis.* 2010, 52:51-58
12. S. Ravi, Y. Darwis, N. Khan, Development and validation of an RP-HPLC-UV method for analysis of sumatriptan succinate in pharmaceutical dosage forms, *Acta Chromatogr.* 21 (2009) 421-432.
13. L. Singh, S. Nanda, R. Chomwal, A validated sensitive chromatographic method for the estimation of sumatriptan succinate in bulk drug and tablet dosage form, *Chron. Young Sci.* 2 (2011) 37-41.
14. Buridi. kalyana ramu* and K. Raghubabu. Estimation of sumatriptan succinate in bulk and formulations by visible spectrophotometry using aromatic aldehydes. *International J of Applied Biology and Pharm tech* 2011; Volume: 2: Issue-1: 86-91.
15. Rajesh Kumar N, Sunil Kumar S, Susanta Kumar P. Method development and validation of Sumatriptan in bulk and pharmaceutical dosage forms by UV spectrophotometric method. *International journal of pharmaceutical and biological archives*, 2011; 2: 1100-1105.
16. Kalyanaramu B, Raghubabu K. A simple visible spectrophotometric determination of Sumatriptan Succinate from pharmaceutical formulations. *Der pharma chemical*, 2011; 3: 223-228.

17. Amruta B.K, Upendra C.G, Shrikant W, Santhakumari B. Development and validation of a sensitive bio-analytical method for the determination of sumatriptan in rat plasma by UPLC-MS. International journal of pharmacy and pharmaceutical sciences, 2013; 5: 78-82.
18. Shah C R*, Suhagia B N, Shah N J, and Shah R R. Development and validation of a HPTLC method for the estimation of Sumatriptan in tablet dosage forms. Indian J of Pharm Sci 2008; Nov-Dec 70 (6): 831–834.
19. ICH Harmonized Tripartite Guidelines. Validation of analytical Procedures: Text and Methodology Q2 (R1) 2005.